Fabre-Kramer Pharmaceuticals
 |
 | |
| Company type | S Corporation |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1992 |
| Headquarters | Houston, Texas |
Key people | Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO) |
| Products | Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD |
| Website | www.fabrekramer.com |
Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include Travivo and FKB01MD for major depression, Travivo and FKW00GA for generalized anxiety disorder, Travivo for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[1]
The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[2][3][4]
References
- ^ "Product Pipeline". Fabre Kramer Pharmaceuticals. Retrieved 2011-10-16.
- ^ Fabre LF, Smith LC (August 2011). "The Effect of Major Depression on Sexual Function in Women". J Sex Med. 9 (1): 231–9. doi:10.1111/j.1743-6109.2011.02445.x. PMID 21883948.
- ^ Fabre LF, Smith LC, DeRogatis LR (September 2011). "Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain--a post hoc analysis". J Sex Med. 8 (9): 2569–81. doi:10.1111/j.1743-6109.2011.02330.x. PMID 21707926.
- ^ Fabre LF, Brown CS, Smith LC, Derogatis LR (May 2011). "Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women". J Sex Med. 8 (5): 1411–9. doi:10.1111/j.1743-6109.2011.02216.x. PMID 21324094.
External links
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |